載入中
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
前收盤價
US$12.75
+US$1.74 · +15.80%
盤前
US$12.65
−US$0.10 · -0.78%
10月12日 上午8:16 ET
盤中時間採用ET。市場資料可能有所延遲。
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
日內區間
目前US$12.75
52週區間
目前US$12.75
盤中時間採用ET。市場資料可能有所延遲。
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
日內區間
目前US$12.75
52週區間
目前US$12.75
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 11.23億 USD | 6.82億 USD | 5.56億 USD | 15.99億 USD | 1.98億 USD |
| 銷貨成本 | 7114萬 USD | 2.03億 USD | 3.44億 USD | 9.03億 USD | — |
| 毛利 | 10.52億 USD | 4.79億 USD | 2.13億 USD | 6.96億 USD | 1.98億 USD |
| 研究與開發 | 3.37億 USD | 3.91億 USD | 7.38億 USD | 12.35億 USD | 25.35億 USD |
| 銷售、一般及管理費用 | 1.5億 USD | 3.37億 USD | 4.69億 USD | 4.89億 USD | 2.98億 USD |
| 營業費用 | 4.89億 USD | 7.28億 USD | 7.79億 USD | 13.41億 USD | 18.84億 USD |
| 利息支出 | 2254.7萬 USD | 2007.5萬 USD | 1441.6萬 USD | 1988萬 USD | 2112.7萬 USD |
| 折舊和攤銷 | 2761.3萬 USD | 4849.6萬 USD | 4122.5萬 USD | 2905.4萬 USD | 1266.1萬 USD |
| 營業利益 | 5.63億 USD | −2.49億 USD | −5.67億 USD | −6.45億 USD | −16.87億 USD |
| 淨利 | 4.4億 USD | −1.87億 USD | −5.45億 USD | −6.58億 USD | −17.44億 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
